Clinicopathologic and molecular features associated with patient age in gastric cancer

Table 7 Univariate and multivariate analyses of predictors for mortality

Parameter	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age ( ≤ 45/> 45 yr)	1.10 (0.72-1.66)	0.664
Gender (male/female)	0.87 (0.63-1.19)	0.384
Curative resection (no/yes)	6.38 (4.33-9.40)	< 0.001
CEA	1.00 (1.00-1.00)	< 0.001
CA19-9	1.00 (1.00-1.00)	< 0.001
Size, cm	1.24 (1.20-1.28)	< 0.001
Pathology
Intestinal	1.00 (reference)
Diffuse	2.77 (2.03-3.78)	< 0.001
Mixed	1.95 (0.89-4.26)	0.095
T stage (III, IV vs I, II)	26.07 (16.42-41.40)	< 0.001
N stage (N+ vs N-)	21.29 (12.81-35.36)	< 0.001
M stage (M+ vs M-)	42.17 (30.75-57.84)	< 0.001	6.70 (1.58-24.49)	0.010
Stage (III, IV vs I, II)	46.39 (30.75-69.98)	< 0.001	10.78 (2.69-43.22)	0.001
Lymphatic invasion (yes/no)	11.84 (7.45-18.83)	< 0.001
Venous invasion (yes/no)	14.75 (9.95-21.87)	< 0.001
Perineural invasion (yes/no)	14.34 (9.42-251.85)	< 0.001
Atrophic gastritis	1.06 (0.77-1.45)	0.736
Intestinal metaplasia	1.00 (0.76-1.30)	0.977
p53 (positive/negative)	1.45 (0.99-2.12)	0.058
MSI (MSI-L vs stable)	1.30 (0.53-3.21)	0.565
MSI (MSI-H vs stable)	0.82 (0.53-1.76)	0.602
HER-2 (positive/negative)	0.57 (0.26-1.25)	0.158
EGFR (positive/negative)	0.66 (0.27-1.65)	0.377

CA 19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; EGFR: Epidermal growth factor receptor; HER-2: Human epidermal growth factor receptor-2; MSI: Microsatellite instability; MSI-H: MSI-high; MSI-L: MSI-low.